Assessing Eligibility for Apomorphine Therapy in Parkinson's Disease: The Telemonitoring Potential
Movement Disorders Clinical Practice · 2025
DOI: 10.1002/mdc3.14345 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, 2025. Verfasst von Alagaratnam Niruban und 9 weiteren Autor:innen. Beteiligte Einrichtung: Norfolk and Norwich University Hospital, Norwich, United Kingdom. Hauptthemen laut MEDLINE: Apomorphine, Parkinson Disease, Antiparkinson Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Britannia Pharmaceuticals.
Abstract (Originalsprache)
Background
Although there are established guidelines for the selection of suitable candidates, objective and timely referral for the use of apomorphine remains challenging.
Objectives
This research examined how telemonitoring may facilitate referrals for continuous subcutaneous apomorphine infusion in Parkinson's disease (PD).
Methods
A Blind Rater and a multi‐disciplinary team (MDT) including an expert PD nurse, neurologist, and geriatrician determined apomorphine pump treatment eligibility for 20 patients with PD. The MDT considered telemonitoring data and physical examination to determine eligibility. The Blind Rater used only telemonitoring data (PDMonitor®) to evaluate eligibility.
Results
The results show that using wearable sensors to determine appropriateness of apomorphine pump treatment is similar to a complete method that combines objective motor symptom monitoring with clinical evaluation. The MDT and blind rater had a 0.89 Cohen's kappa coefficient, which suggests high rate of agreement. The best‐performing objective metric for differentiating patients who were recommended (APO) from those non‐recommended (non‐APO) for apomorphine pump therapy, was the device‐reported percentage of time in the “ON” state, which takes into consideration the “OFF” and dyskinesia time. The APO group had lower values in this metric and could be differentiated from the non‐APO group accurately (85%).
Conclusions
Using telemonitoring to determine eligibility for apomorphine therapy might improve evaluation and treatment in patients with PD and, therefore help improve their quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Norfolk and Norwich University Hospital, Norwich, United Kingdom.
- Department of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
- PD Neurotechnology Ltd., Ioannina, Greece.
- University Hospital of Ioannina and Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
ORCID-Profile: Spyridon Kontaxis, Spyridon Konitsiotis
Förderung
- Britannia Pharmaceuticals
Zitieren
APA
Niruban, A., Dostal, V., Mutimer, A., Tsamis, K., Kontaxis, S., Kostikis, N., Kanellos, F., Ntanis, A., Rigas, G., & Konitsiotis, S. (2025). Assessing Eligibility for Apomorphine Therapy in Parkinson's Disease: The Telemonitoring Potential. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.14345
Vancouver
Niruban A, Dostal V, Mutimer A, Tsamis K, Kontaxis S, Kostikis N, et al. Assessing Eligibility for Apomorphine Therapy in Parkinson's Disease: The Telemonitoring Potential. Movement Disorders Clinical Practice. 2025. doi:10.1002/mdc3.14345
BibTeX
@article{Niruban2025,
author = {Niruban, Alagaratnam and Dostal, Vaclav and Mutimer, Abigail and Tsamis, Konstantinos and Kontaxis, Spyridon and Kostikis, Nicholas and Kanellos, Foivos and Ntanis, Adamantios and Rigas, George and Konitsiotis, Spyridon},
title = {Assessing Eligibility for Apomorphine Therapy in Parkinson's Disease: The Telemonitoring Potential},
journal = {Movement Disorders Clinical Practice},
year = {2025},
doi = {10.1002/mdc3.14345}
}
EUVIMED